Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission

SK Sarin, M Kumar, M Eslam, J George… - The lancet …, 2020 - thelancet.com
Summary The Asia-Pacific region is home to more than half of the global population and
accounted for 62· 6% of global deaths due to liver diseases in 2015. 54· 3% of global deaths …

[HTML][HTML] Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis

N Iragorri, E Spackman - Public health reviews, 2018 - Springer
Background Screening is an important part of preventive medicine. Ideally, screening tools
identify patients early enough to provide treatment and avoid or reduce symptoms and other …

[HTML][HTML] Cost-effectiveness of chronic hepatitis C screening and treatment

HW Lee, H Lee, BK Kim, Y Chang… - Clinical and Molecular …, 2022 - ncbi.nlm.nih.gov
Hepatitis C virus (HCV) infection is the second most common cause of chronic liver disease
in South Korea, with a prevalence ranging from 0.6% to 0.8%, and HCV infection incidence …

[PDF][PDF] Hepatitis C virus elimination by 2030: conquering mount improbable

RK Dhiman, M Premkumar - Clinical liver disease, 2020 - Wiley Online Library
Hepatitis C Virus Elimination by 2030: Conquering Mount Improbable Page 1 254 |CliniCal
liver Disease, vOl 16, nO 6, DeCeMBer 2020 An Official Learning Resource of AASLD review …

[HTML][HTML] Development of genome engineering technologies in cattle: from random to specific

SY Yum, KY Youn, WJ Choi, G Jang - Journal of animal science and …, 2018 - Springer
The production of transgenic farm animals (eg, cattle) via genome engineering for the gain
or loss of gene functions is an important undertaking. In the initial stages of genome …

[HTML][HTML] A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: a societal perspective

HL Kim, KA Kim, GH Choi, ES Jang, M Ki… - Clinical and …, 2022 - ncbi.nlm.nih.gov
Methods A published decision-tree plus Markov model was used to compare the expected
costs and quality-adjusted life years (QALY) between one-time universal HCV screening …

[HTML][HTML] Healthcare value of implementing hepatitis C screening in the adult general population in Spain

M Buti, R Domínguez-Hernández, MÁ Casado… - PloS one, 2018 - journals.plos.org
Background Elimination of hepatitis C virus (HCV) infection requires high diagnostic rates
and universal access to treatment. Around 40% of infected individuals are unaware of their …

[HTML][HTML] Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies

C Krauth, S Rossol, G Ortsäter, A Kautz, K Krüger… - BMC infectious …, 2019 - Springer
Background Chronic hepatitis C is a major public health burden. With new interferon-free
direct-acting agents (showing sustained viral response rates of more than 98%), elimination …

Population health and cost-effectiveness implications of a “treat all” recommendation for HCV: a review of the model-based evidence

LE Cipriano, JD Goldhaber-Fiebert - MDM policy & practice, 2018 - journals.sagepub.com
The World Health Organization HCV Guideline Development Group is considering a “treat
all” recommendation for persons infected with hepatitis C virus (HCV). We reviewed the …

[HTML][HTML] HCV core antigen comes of age: a new opportunity for the diagnosis of hepatitis C virus infection

C Galli, P Julicher, M Plebani - Clinical Chemistry and Laboratory …, 2018 - degruyter.com
The diagnosis of hepatitis C virus (HCV) infection has been traditionally based on the
detection of the host antibody response. Although antibody assays are available in different …